Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Achieved First Quarter 2019 TEGSEDI® (inotersen) Global Net Product Revenues of $7 Million Novartis exercised its option to license AKCEA-APO(a)-LRx Received marketing authorization for WAYLIVRA®...
-
NEURO-TTR phase 3 open-label extension study showed TEGSEDI® (inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR amyloidosis with polyneuropathy ...
-
BOSTON and CARLSBAD, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS),...
-
Multiple clinical presentations at AAN focus on the long-term clinical benefits of treatment with TEGSEDI™ (inotersen) An oral presentation of long-term efficacy and safety with 2-year data from...
-
BOSTON, April 24, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Wednesday, May 8th...
-
BOSTON and CARLSBAD, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)...
-
Бостон и Карлсбад, March 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (биржевый символ NASDAQ:AKCA), подразделение Ionis Pharmaceuticals, Inc., и Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
-
BOSTON, Massachusetts, y CARLSBAD, California, March 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics , Inc. (NASDAQ: AKCA), una filial de Ionis Pharmaceuticals, Inc., e Ionis Pharmaceuticals, Inc....
-
BOSTON, Massachusetts und CARLSBAD, Kalifornien, March 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), ein Tochterunternehmen von Ionis Pharmaceuticals, Inc. und Ionis...
-
BOSTON, Mass. en CARLSBAD, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), een gelieerde onderneming van Ionis Pharmaceuticals, Inc., en Ionis Pharmaceuticals,...